此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

NRX-101 扩展访问 (NRX-101 EAP)

2026年9月16日 更新者:NeuroRx, Inc.

NRX-101 用于治疗有自伤风险的难治性双相抑郁症患者

The purpose of this Expanded Access Treatment Protocol is to make NRX-101 available to patients who have treatment-resistant depression and who are unable to participate in, or do not have access to, the ongoing NRX-101 clinical trial. The objective of the program is to provide treatment access while monitoring safety in the context of NRX-101 administration paired with theta burst transcranial magnetic stimulation..

研究概览

详细说明

This Expanded Access Protocol is intended for patients with treatment-resistant depression with or without suicidal ideation, conditions that are serious and potentially life-threatening. Many patients in this population do not achieve adequate benefit from currently approved pharmacologic and nonpharmacologic treatments and therefore lack satisfactory therapeutic alternatives. Available clinical and mechanistic data for NRX-101 suggest a potential for clinically meaningful benefit when administered in conjunction with TMS, and the anticipated benefits are considered to justify the potential risks in this population. Access under this program is limited to patients who are not eligible for, or cannot reasonably participate in, the ongoing clinical trial (NRX101-011), or enrollment is capped, such that this program will not interfere with the initiation, conduct, or completion of the clinical development program.

研究类型

扩展访问

扩展访问类型

  • 中型人口

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Massachusetts
      • Belmont、Massachusetts、美国、02478
        • 可用的
        • Harvard Mclean Hospital

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不适用

有资格学习的性别

全部

描述

Inclusion Criteria:

-

Eligible for inclusion in this EAP only if all the following criteria apply:

  1. 18 years of age or older

  2. Able to understand the study procedures and risks and able to provide written and dated informed consent before any protocol-specific procedure.

  3. In the investigator's judgment, likely to comply with the Expanded Access Protocol, including transcranial magnetic stimulation visits, NRX-101 dosing instructions, scheduled assessments, and prompt communication of adverse events and other clinically important information.

  4. Under the care of a board-certified psychiatrist or other qualified psychiatric prescriber who has completed protocol-specific training, is registered as an investigator for this Expanded Access Protocol, and agrees to direct and document the patient's psychiatric care according to standard of care.

  5. Diagnosed with treatment resistant depression (TRD) according to the criteria defined in the DSM-5. This diagnosis must be made by a psychiatrist or other qualified licensed psychiatric provider.

  6. History of inadequate response, intolerance, or loss of effect to at least one prior adequate pharmacologic treatment for the current depressive episode with a medication indicated for treatment-resistant depression in the investigator's judgment.

  7. Planned course of theta burst transcranial magnetic stimulation as part of standard clinical care for the current depressive episode, to be delivered at a site with appropriate experience and safety procedures for transcranial magnetic stimulation.

  8. No uncontrolled or unstable medical condition that, in the investigator's judgment, creates an unacceptable risk with theta burst transcranial magnetic stimulation in combination with NRX-101 or prevents adequate assessment of safety.

  9. If heterosexual female, a status of non-childbearing potential or use of an acceptable form of birth control per the following criteria, and agrees to continue use of the same method of birth control for the duration of treatment with NRX-101:

    1. Non-childbearing potential: physiologically incapable of becoming pregnant (i.e., permanently sterilized [status post-hysterectomy, bilateral tubal ligation], or post-menopausal with last menses at least one year prior to Screening); or
    2. Childbearing potential, and meets the following criteria:

    i. Use of any form of hormonal birth control for at least 2 months prior to Screening, on hormone replacement therapy that started prior to 12 months of amenorrhea, using an intrauterine device (IUD) for at least 1 month prior to Screening, in a monogamous relationship with a partner who has had a vasectomy, or sexually abstinent.

    ii. Negative urinary pregnancy test at Screening, confirmed by a second negative urinary pregnancy test at Day 1, prior to receiving treatment with NRX-101.

  10. Sufficient stability of residence and contact information to allow appropriate follow up and emergency contact during participation in the Expanded Access Protocol, in the investigator's judgment.

  11. The patient is not participating in and cannot reasonably enroll in the concurrent Phase IIb trial NRX101-011, because the patient does not meet at least one inclusion criterion for NRX101-011, meets at least one exclusion criterion for NRX101-011, or faces distance, transportation, schedule, or other practical barriers that prevent trial participation despite interest. The investigator must document the specific reason in the source record.

Exclusion Criteria:

  1. Heterosexual female of childbearing potential who is not willing to use one of the specified forms of birth control during the study.

  2. Female who is pregnant (positive pregnancy test at Screening) or breastfeeding.

  3. Active suicidality (without the intention to act) as evidenced by a score of >3 on the Columbia Suicide Severity Rating Scale.

  4. Current DSM-5 diagnosis of moderate or severe substance use disorder (except marijuana or tobacco use disorder) within the 12 months prior to Screening. (Note: Substance use disorder cannot be the precipitant for study entry).

  5. Current DSM-5 diagnosis of alcohol use disorder

  6. A lifetime history of phencyclidine (PCP)/ketamine drug abuse

  7. History of schizophrenia or schizoaffective disorder

  8. History of anorexia nervosa, bulimia nervosa, eating disorder not otherwise specified (NOS), or other specified feeding and eating disorders (OSFED) within 3 years of Screening.

  9. Has dementia, delirium, amnestic, or any other cognitive disorder.

  10. Renal impairment defined as estimated glomerular filtration rate (eGFR) < 60 mL/min, calculated using the 2021 CKD-EPI creatinine equation (race-free).

  11. Clinically significant hepatic impairment. Clinically significant hepatic impairment is defined as a history of chronic liver disease (e.g., cirrhosis, chronic hepatitis, alcoholic liver disease, nonalcoholic steatohepatitis) or evidence at Screening of acute liver disease or impaired liver function (e.g., ALT or AST >3 × ULN, total bilirubin >2 × ULN) or in the opinion of the Investigator.

  12. A clinically significant abnormality on the Screening physical examination that may affect safety or study participation, or that may confound interpretation of study results according to the study clinician.

  13. Risk factors for neurocardiogenic syncope including history of syncope/ presyncope related to noxious stimuli, anxiety, micturation, or posture.

  14. Co-morbidities as ascertained by medical history, physical examination (including measurement of vital signs), clinical laboratory evaluations, and electrocardiogram (ECG) which might interfere with compliance or the ability to assess efficacy or safety.

  15. Diagnosis of moderate to severe heart disease or current episode of:

    1. Myocardial infarction within 1 year of Screening.
    2. Diagnosis of angina pectoris.
    3. Prolonged QTc interval, as measured by Fridericia's correction formula (QTcF) ≥450 msec at Screening for males or ≥ 470 msec for females on 2 of 3 measurements at least 15 minutes apart prior to randomization on Day 1.
  16. Diagnosis of chronic lung disease, excluding asthma.

  17. Lifetime history of any of the following: neurologic conditions with structural cerebral damage, traumatic brain injury, multiple sclerosis, surgical procedures involving the brain or meninges, meningoencephalitis, degenerative central nervous system (CNS) disorder (e.g., Alzheimer's Disease, Parkinson's Disease), mental retardation, stroke (ischemic or hemorrhagic), intracranial abscess, or any other disease/procedure/accident/intervention that, according to the clinician, is deemed associated with significant injury to, or malfunction of, the CNS.

  18. History of epilepsy, personal history of seizure, family history of epilepsy or seizure in a first degree relative.

  19. Diagnosis of parenchymal or leptomeningeal cancer.

  20. Diabetes mellitus fulfilling any of the following criteria:

    1. Unstable diabetes mellitus defined as glycosylated hemoglobin (HbA1c) >8.0 percent at Screening.
    2. Admitted to the hospital for treatment of diabetes mellitus or diabetes mellitus-related illness in the past 12 weeks.
    3. Not under physician care for diabetes mellitus.
    4. Not on the same dose of oral hypoglycemic drug(s) and/or diet for the 4 weeks prior to Screening.
    5. Not on the same dose of oral thiazolidinediones (glitazones) for the 8 weeks prior to Screening.
  21. Any current or past history of any physical condition which, in the opinion of the investigator, may put the patient at risk or interfere with study results interpretation.

  22. On exclusionary concomitant psychotropic and non-psychotropic medications (see Section 9.5)

  23. Prescribed more than one agent in each of the following categories at randomization:

    1. Approved SSRIs.
    2. Approved serotonin and norepinephrine reuptake inhibitors (SNRIs).
    3. Approved tetracyclic antidepressants (TeCAs).
  24. Currently prescribed oxcarbazepine or carbamazepine.

  25. Exclusionary laboratory values or any other clinically significant abnormal laboratory result at Screening. Within normal limits (WNL) will be determined based on lab values of the local lab used.

  26. Known allergies to lurasidone or Latuda®, cycloserine or Seromycin®, or the following excipients: mannitol, croscarmellose sodium, magnesium stearate, silicon dioxide, and/or hydroxypropylmethylcellulose (HPMC).

  27. Participation in any clinical trial with an investigational drug or device within the past 3 months or planned concurrent study participation.

  28. Study site personnel and/or persons employed by NRx Pharma, Inc., the Contract Research Organization (CRO), the investigator, or study site (i.e., permanent, temporary contract worker, or designee responsible for the conduct of the study), or an immediate family member (i.e., spouse, parent, child, or sibling [biological or legally adopted]) of such persons.

  29. Positive urine toxicity screening for use of any cocaine, opiates, non-prescribed amphetamines, or non-prescribed barbiturates. (Note: cannabinoids or marijuana use is not exclusionary, unless patient meets the DSM-5 criteria for cannabis withdrawal).

  30. Patients with pacemakers and/or any implants including metal in the head except the mouth (cochlear implant, implanted brain stimulators, aneurysm clips)

  31. Individuals with an intracranial lesion or increased intracranial pressure

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

赞助

调查人员

  • 首席研究员:Jonathan C Javitt, MD, MPH、NRx Pharma, Inc.

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究注册日期

首次提交

2023年3月8日

首先提交符合 QC 标准的

2023年3月8日

首次发布 (实际的)

2023年3月22日

研究记录更新

最后更新发布 (实际的)

2026年9月17日

上次提交的符合 QC 标准的更新

2026年9月16日

最后验证

2026年9月1日

更多信息

与本研究相关的术语

其他研究编号

  • NRX101-012 EAP

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅